US 12,325,744 B2
Methods for reducing post-operative cognitive dysfunction (POCD)
Mervyn Maze, San Francisco, CA (US); Marc Feldmann, London (GB); Niccolo Terrando, San Francisco, CA (US); Mario Cibelli, London (GB); Daqing Ma, London (GB); Michael Fertleman, London (GB); and Jagdeep Nanchahal, Oxford (GB)
Assigned to THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH, London (GB)
Filed by The Kennedy Trust for Rheumatology Research, London (GB)
Filed on Dec. 20, 2021, as Appl. No. 17/556,584.
Application 15/063,775 is a division of application No. 13/579,555, granted, now 9,308,254, issued on Apr. 12, 2016, previously published as PCT/GB2011/000220, filed on Feb. 17, 2011.
Application 17/556,584 is a continuation of application No. 16/661,769, filed on Oct. 23, 2019, granted, now 11,220,540.
Application 16/661,769 is a continuation of application No. 15/063,775, filed on Mar. 8, 2016, abandoned.
Claims priority of provisional application 61/305,500, filed on Feb. 17, 2010.
Prior Publication US 2022/0112281 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 31/546 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/525 (2006.01); C12N 15/113 (2010.01)
CPC C07K 16/241 (2013.01) [A61K 31/546 (2013.01); A61K 31/713 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 14/525 (2013.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01)] 12 Claims
 
1. A method for reducing post-operative cognitive dysfunction (POCD) in a patient resulting from a surgical procedure on the patient which comprises administering to the patient during the surgical procedure a therapeutically effective amount of an anti-Human Tumor Necrosis Factor alpha (TNFα) monoclonal antibody, wherein the anti-Human TNFα monoclonal antibody binds to, and blocks the action of, Human TNF alpha so as to reduce POCD in the patient, wherein the anti-Human TNF alpha monoclonal antibody is adalimumab.